EMPOWERING CLINICAL SCIENCE
To enhance cardiovascular care
Cardiovascular diseases are the #1 killer of women globally.
Yet, the majority of the medical device industry and clinical research is male-centric.
Participants in cardiovascular clinical trials
Less than 40% of people taking part in cardiovascular clinical trials are women.¹
This results in a gap in knowledge and understanding of women's specific conditions. It leads to inadequate or inappropriate management of cardiac disease in women.²
Epsidy is committed to changing the status quo.
Epsidy develops a wearable garment to enhance exam efficiency and comfort for all patients, be they female or male.
In addressing the challenge of diagnosing heart disease in women, Epsidy’s efforts also apply to men, who have similar chest structure to women, but without breasts.
Epsidy has been recognized by FemTech France, which supports the creation of innovative projects dedicated to women's health.
THEY TRUST US
Epsidy is actively involved in several research programs.
Public universities and medical device manufacturers who have initiated a collaboration with Epsidy include:
Get in touch.
We’d love to hear from you.
Be the first to act with us, either to make a career choice, to invest in our cause, or to partner with us.
Sources and references
Jin X, Chandramouli C, Allocco B, Gong E, Lam CSP, Yan LL. Women’s Participation in Cardiovascular Clinical Trials From 2010 to 2017. Circulation. 2020 Feb 18;141(7):540–8.
Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. The Lancet [Internet]. 2021 May;397(10292). Available from: https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900684-X